PRIMARY STUDY
The current status of artisanal cannabis for the treatment of epilepsy in the United States
Key Findings: This case series and meta-analysis found that 86% of cannabis users for seizures control had some benefit. Four specific case reports are further outlined providing evidence of clinical responses at doses <0.1mg/kg/day, biphasic dose-response effects, THCA as seizure prevention, THC for seizure rescue, and the synergy of cannabinoids and terpenoids in artisanal preparations.
Type of Study: Meta-analysis
Study Sample Size: 272
Study Result: Positive
Research Location(s): United States
Year of Pub: 2017
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Pharma CBD, Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype III
DOSING DETAILS 
Study Dosing Objective: Effective Dose, Safety Profile, Synergistic Dose,
Established Protocol: Effective dose
Cannabinoid Ratio: (CBD) 0 
Dosage Form: artisanal cannabis preparations
Clinical Relevance: Four case reports found clinical responses at doses <0.1mg/kg/day.
Adverse Events: mild and infrequent
Citation: Sulak D, Saneto R, Goldstein B. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy Behav. 2017 May;70(Pt B):328-333. doi: 10.1016/j.yebeh.2016.12.032. Epub 2017 Feb 21. PMID: 28254350.
